Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GS-248 for Raynaud's phenomenon in systemic sclerosis
NL-OMON52928Phase 2Completed
- Sponsor
- Gesynta Pharma
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vipoglanstat in Raynaud disease and systemic sclerosis (SSc), sponsored by Gesynta Pharma. Primary endpoints: Mean change from baseline to week 4 in number of Raynaud's phenomenon attacks per week, Incidence of adverse events and 2 more. Started Feb 2021; status: completed.
02
Drugs
vipoglanstat
03
Conditions
Raynaud diseasesystemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON52928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52928.